Home/Pipeline/RZ-520

RZ-520

Immune & Inflammatory Disease

PreclinicalActive

Key Facts

Indication
Immune & Inflammatory Disease
Phase
Preclinical
Status
Active
Company

About Rezubio

Rezubio develops gut-restricted drugs using its Membrane-Anchored Drug Design platform to create safer, more effective treatments for metabolic and inflammatory diseases.

View full company profile